HDL Therapy Under Development

High density lipoprotein (HDL) therapy is based on a patented process that selectively and rapidly removes lipids from lipoproteins such as HDL without harming the proteins that carry the lipid particles.

This therapy is to have the ability to boost high density lipoprotein efficiency and thereby the potential to reduce the risk of cardiovascular disease. The therapy is being developed by Lipid Sciences, Inc. (Pleasanton, CA, USA; www.lipidscience.com) along a parallel path with its viral immunotherapy platform. This new technology, focused on the removal of lipid coatings from viruses and other lipid-containing infectious agents, is called delipidation. Lipid Sciences has initiated a series of nonhuman primate studies to further validate the technology. The goal of these studies is the development of a therapeutic vaccine approach for use against HIV.

"Based on recent positive in vitro results from our HDL therapy development program, we believe that our practical, cost-effective proprietary delipidation process has the ability to boost HDL efficiency in reverse cholesterol transport and turn back the ‘cardiovascular clock' by reversing the build-up of fatty plaque in coronary arteries,” said Dr. S. Lewis Meyer, president and CEO of Lipid Sciences. The company is currently considering various initiatives, including evaluating recent third-party inquiries, to determine the best way to capitalize on the market opportunity represented by its HDL therapy.




Related Links:
Lipid Sciences